Here we describe MyGene2, Geno2MP, VariantMatcher, and Franklin; databases that provide variant-level information and phenotypic features to researchers, clinicians, healthcare providers and patients. Following the footsteps of the Matchmaker Exchange project that connects exome, genome, and phenotype databases at the gene level, these databases have as one goal to facilitate connection to one another using Data Connect, a standard for discovery and search of biomedical data from the Global Alliance for Genomics and Health (GA4GH).
DMJD patients have biallelic mutations in PCDH12 and lack of protein expression. These patients present with characteristic microcephaly and abnormalities of white matter tracts. Such pathogenic variants predict a poor outcome as a result of brainstem malformation and evidence of white matter tract defects, and should be added to the phenotypic spectrum associated with PCDH12-related conditions. Ann Neurol 2018;84:646-655.
Background: Interpretation of genetic variation remains an impediment to cost-effective application of genomics to medicine. An advanced artificial intelligence (AI)-based Variant Classification Engine (aiVCE), rooted in ACMG/AMP guidelines, employs data-driven methods to expedite gene-specific classification (franklin.genoox.com). In this blinded study, the aiVCE’s overall and rule-level performances were evaluated using ClinVar (v. 2018-10) variants with creation dates after 5/01/2017. By removing any prior knowledge of these variants from the aiVCE training data, they were treated as novel variants. Using a ‘Full’ dataset (75,801 variants with ≥1 star) and an ‘Increased-Certainty’ dataset (3,993 variants with ≥2 stars), the aiVCE classified variants as pathogenic (P), likely-pathogenic (LP), uncertain significance (VUS), likely-benign (LB), or benign (B). VUS with sufficient supporting data were subclassified as VUS-leaning benign or VUS-leaning pathogenic. aiVCE results were evaluated to determine concordance with final ClinVar classification and rule-level determinations. Results: The aiVCE demonstrated >97% concordance among Increased-Certainty variants. Concordance was >95% across variant effects (e.g., missense, null, splice region), and was >93.5% for the Full dataset. When assessing the aiVCE’s application of specific ACMG rules, significant differences were observed between ClinVar P/LP and B/LB variants rule-met proportions (all P<0.00001), thus supporting gene-specific rule selections. Evaluation of discordance between the aiVCE and ClinVar uncovered evidences that might have been unavailable to submitting laboratories, highlighting AI utility in variant classification. Conclusions: The aiVCE exhibited robust performance, despite lacking past evidence, in determining whether variants would be categorized as P/LP. Applying latest computational advances to existing guidelines may assist scientists and clinicians interpret variants with limited clinical information and greatly reduce analytical bottlenecks.
Sequencing large cohorts of ethnically homogeneous individuals yields genetic insights with implications for the entire population rather than a single individual. In order to evaluate the genetic basis of certain diseases encountered at high frequency in the Ashkenazi Jewish population (AJP), as well as to improve variant annotation among the AJP, we examined the entire exome, focusing on specific genes with known clinical implications in 128 Ashkenazi Jews and compared these data to other non-Jewish populations (European, African, South Asian and East Asian). We targeted American College of Medical Genetics incidental finding recommended genes and the Catalogue of Somatic Mutations in Cancer (COSMIC) germline cancer-related genes. We identified previously known disease-causing variants and discovered potentially deleterious variants in known disease-causing genes that are population specific or substantially more prevalent in the AJP, such as in the ATP and HGFAC genes associated with colorectal cancer and pancreatic cancer, respectively. Additionally, we tested the advantage of utilizing the database of the AJP when assigning pathogenicity to rare variants of independent whole-exome sequencing data of 49 Ashkenazi Jew early-onset breast cancer (BC) patients. Importantly, population-based filtering using our AJP database enabled a reduction in the number of potential causal variants in the BC cohort by 36%. Taken together, population-specific sequencing of the AJP offers valuable, clinically applicable information and improves AJP filter annotation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.